Drugs / EBV immunological agent
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06666153 | Oct 2024 → Dec 2025 overdue | Epstein-Barr virus infection, post-transplant lymphoproliferative disease | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05707910 | Feb 2023 → Apr 2024 overdue | cancer | West China Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV immunological agent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05707910 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT05707910 ↗ |